352 results
Page 9 of 18
8-K
EX-99.1
zav05 yvgldg8z
27 Jan 14
BioTime, Inc. Subsidiary OncoCyte Corporation Initiates Clinical Development of Bladder Cancer Diagnostics in the United States and China
12:00am
8-K
EX-99.1
bt1oq
17 Jan 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
nrywnt
13 Jan 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
7ar 43vcavupimsy
2 Jan 14
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Leases Facilities for Expanded Product Development and Manufacturing
12:00am
8-K
EX-99.1
bvkwxv4 51g
23 Dec 13
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist
12:00am
8-K
EX-99.1
br340 tc7tftxuqb
6 Dec 13
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.11
12:00am
8-K
EX-99.1
0hwohglaqt v8
4 Dec 13
BioTime’s CEO, Dr. Michael West to Moderate Session on Mapping the Cellular Basis of Life at the 2013 World Stem Cell Summit
12:00am
8-K
EX-99.1
8ni37d5rlzlfvlin
2 Dec 13
Asterias Biotherapeutics, Inc. Files Registration Statement for Underwritten Public Offering
12:00am
8-K
EX-99.1
yqeznlqs
25 Nov 13
BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference
12:00am
8-K
EX-99.1
3gz3n
28 Oct 13
BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
12:00am
8-K
EX-99.1
erx4mvqt4 f7luu
28 Oct 13
Regulation FD Disclosure
12:00am
8-K
EX-99.1
3xqyt7zmakl 6mkorf
28 Oct 13
BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
12:00am
DEFA14A
7qtoy3lh5x6bjm7y
7 Oct 13
Additional proxy soliciting materials
12:00am
8-K
2eopkq3xwk32bxddbcct
4 Oct 13
BioTime Announces Additional Products in Development Based on HyStem® Technology
12:00am
8-K
EX-99.1
gasdj8jkulqy
4 Oct 13
BioTime Announces Additional Products in Development Based on HyStem® Technology
12:00am
8-K
EX-99.1
eol7b qs25b46v
1 Oct 13
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets
12:00am
8-K
EX-99.1
d8cg0bgrc
19 Sep 13
BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology
12:00am
8-K
EX-99.1
lx6j8luvzamq qcy
28 Aug 13
BioTime Receives Approval to Begin Human Clinical Trials of Renevia
12:00am
8-K
EX-99.1
64qqywrbwiko0wpjh
21 Aug 13
BioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development
12:00am